Medicare Prescription Drug Benefit, Nonprofit Hospitals, Ambulatory Surgery Centers, Statistical Methods, and Pay-For-Performance Highlighted In the Latest INQUI...(z who has beenthe journal's editor for m...),Health
Navigation Links
Medicare Prescription Drug Benefit, Nonprofit Hospitals, Ambulatory Surgery Centers, Statistical Methods, and Pay-For-Performance Highlighted In the Latest INQUIRY Journal
Date:9/13/2007
z, who has been the journal's editor for more than 11 years (release: http://www.inquiryjournal.org/news/press_release_20070808.html ).
INQUIRY is a peer-reviewed scholarly publication. Now in its 44th year, it is published quarterly by Excellus Health Plan, Inc. Press releases and article abstracts are available at http://www.inquiryjournal.org/.
'/>"/>
| SOURCE INQUIRY journal Copyright©2007 PR Newswire. All rights reserved |
Related medicine news :
1. Medicare Drug Deadline not to be extended
2. House heads for Medicare drug vote
3. New Medicare Plan - Mixed Reaction among Pharmacists.
4. Medicare Data would help in Drug Validation
5. Medicare Queries Expected To Increase Over Time
6. Medicare to cover services provided by rural health care personnels.
7. Cancer test expenses taken up by Medicare
8. Nurse Practitioners Are Not Recognized By Medicare
9. Medicare Drug Plan Is Not Working in The US
10. Blue Cross Signs Up 110,000 Minnesotans For Part D Medicare Plans
11. Rising Medicare costs
Post Your Comments:
Breaking Medicine News(10 mins):Health News:The Visiting Nurse Association of Greater Philadelphia Expands Service to Bucks County 2Health News:'Disease of Poverty': University of South Carolina Releases Journal on Cervical Cancer, Health Disparities 2Health News:'Disease of Poverty': University of South Carolina Releases Journal on Cervical Cancer, Health Disparities 3Health News:Alcohol Countermeasure Systems Penetrates New Markets Through Acquisition of Seres Ethylometre of France 2Health News:Targeted therapy prolongs life in patients with HER2-positive breast cancer 2
[0] Many Stroke Survivors Don't Take Lifesaving Meds[0] The Visiting Nurse Association of Greater Philadelphia Expands Service to Bucks County[0] 'Disease of Poverty': University of South Carolina Releases Journal on Cervical Cancer, Health Disparities[0] Alcohol Countermeasure Systems Penetrates New Markets Through Acquisition of Seres Ethylometre of France[0] Targeted therapy prolongs life in patients with HER2-positive breast cancer
Other Medicine News:Health News:Treatment Advocacy Center Honors Three Grassroots Mental Illness Advocates 2Health News:Agent orange chemical, dioxin, attacks the mitochondria to cause cancer, says Penn research team 2Health News:Robotic device appears useful for surgical removal of cancer involving the tonsils 2Health News:TriWest Contributes $15,000 to New Mexico National Guard Fund 2Health News:Aspreva obtains shareholder approval for acquisition by Galenica 2Health News:Aspreva obtains shareholder approval for acquisition by Galenica 3Health News:Aspreva obtains shareholder approval for acquisition by Galenica 4
Treatment Advocacy Center Honors Three Grassroots Mental Illness AdvocatesAgent orange chemical, dioxin, attacks the mitochondria to cause cancer, says Penn research teamRobotic device appears useful for surgical removal of cancer involving the tonsilsTriWest Contributes $15,000 to New Mexico National Guard FundAspreva obtains shareholder approval for acquisition by Galenica'The Diabetes Educator' publishes systematic reviews for diabetes management
Breaking Medicine Technology:Within3 Expands into Mobile Applications 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2American Chemical Societys Weekly PressPac June 3 2009 8740 1American Chemical Societys Weekly PressPac June 3 2009 8740 2American Chemical Societys Weekly PressPac June 3 2009 8740 3American Chemical Societys Weekly PressPac June 3 2009 8740 4American Chemical Societys Weekly PressPac June 3 2009 8740 5American Chemical Societys Weekly PressPac June 3 2009 8740 6American Chemical Societys Weekly PressPac June 3 2009 8740 7American Chemical Societys Weekly PressPac June 3 2009 8740 8American Chemical Societys Weekly PressPac June 3 2009 8740 9American Chemical Societys Weekly PressPac June 3 2009 8740 10Warner Chilcott to Present at the Goldman Sachs 30th Annual Healthcare Conference 48171 1Video 3A CVS pharmacy Kicks Off 8th Annual ALS Fundraising Campaign in Stores Nationwide 48169 1Video 3A CVS pharmacy Kicks Off 8th Annual ALS Fundraising Campaign in Stores Nationwide 48169 2Video 3A CVS pharmacy Kicks Off 8th Annual ALS Fundraising Campaign in Stores Nationwide 48169 3
[0] Within3 Expands into Mobile Applications[0] Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer[0] Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |